FIELD: medicine.
SUBSTANCE: methods include peroral, transbuccal, sublingual, intranasal, intraocular, intragastric, intraduodenal, local, rectal or vaginal introduction within twenty four hours of the first therapeutically effective amount of E-2-methoxy-N-(3 {4 (3-3-4 (6-methyl-pyridine-3-iloxy)-phenylamino)-chinasolin-6-yl}-allyl)-acetamide (E composition), making 25-100 mg/kg, and the second therapeutically effective amount of E composition making 25-100 mg/kg.
EFFECT: improved therapeutic scheme of ovary adenocarcinoma owing to selection of specified small doses and conditions of E composition introduction.
2 cl, 6 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINAL FORMS CONTAINING AG013736 | 2004 |
|
RU2341263C2 |
| TREATMENT OF BRAIN CANCER | 2013 |
|
RU2672575C2 |
| COMBINATION CONTAINING PALBOCICLIB AND 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDINE-3-YL]-8,9-DIHYDRO-7H-BENZO[7]ANNULENE-2-CARBOXYLIC ACID AND APPLICATION THEREOF FOR TREATING CANCER | 2018 |
|
RU2764116C2 |
| COMBINED ANTICANCER THERAPY | 2011 |
|
RU2607596C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
| USE OF INVERSE AGONISTS OR ANTAGONISTS OF GHRELIN RECEPTOR FOR TREATING SLEEP DISORDERS | 2013 |
|
RU2600895C2 |
| METHOD OF TREATING ABNORMAL CELL EXPANSION | 2006 |
|
RU2384331C2 |
